Omvoh was approved for its first IBD indication, moderately to severely active ulcerative colitis (“UC”), in 2023. The drug is currently approved for UC in 44 countries. The approval of Omvoh ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Lilly said that Omvoh is the only FDA-approved UC treatment that selectively targets the p19 subunit of IL-23, which plays a role in inflammation related to the disease, although Johnson & Johnson ...

Omvoh is currently approved in more than 44 countries, including the United States and Europe, to treat adults with moderate-to-severely active ulcerative colitis (“UC”). Year to date ...